Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Studies have shown that the prevalence of RAS and BRAF mutations may differ by tumor
sidedness among metastatic colorectal cancer (mCRC) patients. Both mutation status and …

Since the establishment of the Sanger sequencing method, scientists around the world
focused their efforts to progress in the field to produce the utmost technology. The …

PURPOSE To describe the clinical and molecular features of metastatic colorectal cancers
(mCRCs) bearing uncommon atypical RAS (At-RAS) mutations at codons other than 12, 13 …

Colorectal cancer is a clinically and molecularly heterogeneous disease. Currently,
extended RAS and BRAF mutation testing is obligatory in routine clinical practice before …

Introduction: Blood draw or collection of other body fluids, known as 'liquid biopsies' are
generally less invasive procedures than tumor biopsies. Cell-free tumor DNA (ctDNA) is …

Introduction Colorectal cancer (CRC) is one of the most prevalent and lethal cancers
worldwide. The treatment of metastatic colorectal cancer (mCRC) is difficult, and mCRC has …

Background Metastatic melanoma is a severe disease with one of the highest mortality rate
in skin diseases. Overall survival has significantly improved with immunotherapy and …

Background Assessment of KRAS, NRAS (RAS) and BRAF mutations is a standard in the
management of patients with metastatic colorectal cancer (mCRC). Mutations could be …

Testicular germ cell tumors (TGCTs) are unique amongst solid tumors in terms of the high
cure rates using chemotherapy for metastatic disease. Nevertheless, TGCTs still kill …